Document is current

Article History

Received: 6 November 2017

Revised: 28 March 2018

Accepted: 10 April 2018

First Online: 25 April 2018

Compliance with ethical standards

: Due to the non-interventional, observational study design, use of a limited dataset (i.e., contains no direct identifiers) is exempt from institutional review board (IRB) and ethics committee (EC) review. Investigative site IRB/EC approval was sought as a best practice in all participating countries. The CORRONA US protocol was reviewed and approved by a central IRB, New England Independent Review Board (NEIRB ID no.: 120160610). Approval for the International protocol was also obtained when review was accommodated by a site’s governing EC.

: DA Pappas financial: Corrona, LLC Employee and Stock Options, Novartis Instructor. Non-financial: none. F Nyberg: employee and shareholder of AstraZeneca. Non-financial: holds an affiliation as Associate Professor at Sahlgrenska Academy, University of Gothenburg, without special remuneration. JM Kremer: Corrona, LLC employment: Corrona, LLC; stock: Corrona, LLC. Consultant: AbbVie, Amgen, BMS, Genentech, Lilly, Pfizer. Non-financial: none. K Lampl: former employee of AstraZeneca, employee of Genentech. Non-financial: none. GW Reed: employee at Corrona, LLC, stock options Corrona, LLC. Non-financial: appointment at the University of Massachusetts. L Horne: former employee of AstraZeneca, employee of Medical Evidence and Observational Research Centre, Global Medicines Development. Non-financial: none. M Ho: Employee AstraZeneca. Non-financial: none. A Onofrei: Corrona, LLC employee. Non-financial: none. A Malaviya: there are no financial or non-financial conflict of interest of the author related to this research work. O Rillo: there are no financial or non-financial conflict of interest of the author related to this research work. SC Radominski: research grants—Pfizer, BMS, AstraZeneca, Amgen, Sanofi, Novartis, Celltrion, Roche; employment: Prof. of Rheumatology—Universidade Federal do Parana–Curitiba, Brazil; consulting fees: Pfizer, BMS, AstraZeneca, speaker’s bureau—Pfizer, BMS, AstraZeneca, Janssen, Sanofi, GSK. Non-financial: Universidade Federal do Paraná. J Gal: there are no financial or non-financial conflict of interest of the author related to this research work. A Gibofsky: consultant—Abbvie, Drais, Celgene, Horizon, Iroko, Medac, Pfizer, Relburn, Samumed, Takeda; speaker—AbbVie, Amgen, Celgene, Iroko, Pfizer. Stockholder—AbbVie, Amgen, BMS, GSK, J&J, Pfizer. Non-financial: none. T Popkova: there are no financial or non-financial conflict of interest of the author related to this research work. I Laurindo: consulting fees—Abbott, AstraZeneca, Bristol, Janssen, Pfizer, speaker’s bureau—Abbott, AstraZeneca, Bristol, Janssen, Pfizer, Roche, UCB. Non-financial: none. E Kerzberg: there are no financial or non-financial conflict of interest of the author related to this research work. R Zahora: there are no financial or non-financial conflict of interest of the author related to this research work. BA Pons-Estel: research grant—GLADAR (Grupo Latino Americano de estudio De Artritis Reumatoidea) have received a research grant from ABBOTT Laboratories. Non-financial: none. JR Curtis: grant/research support—Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie; consultant—Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie. Non-financial: none. D Furst: AbbVie, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB; consultant—AbbVie, Actelion, Amgen, BMS, Cytori, Janssen, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB; speaker’s bureau—Abbvie, Actelion, UCB (CME ONLY). Non-financial: none. JD Greenberg: Corrona, LLC. employee and shareholder—Corrona, LLC.; consultant—AstraZeneca, Celgene, Genentech, Janssen, Novartis and Pfizer. Non-financial: none.